Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 20, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg".